Phibro Animal Health (PAHC) to Release Earnings on Wednesday

Key Points

• Q3 2026 earnings are due after the market close on Wednesday, May 6, with analysts forecasting $0.72 EPS and $365.205 million in revenue, and Phibro has set FY 2026 guidance of $2.93–$3.10 EPS.
• In the prior quarter (reported Feb. 4) Phibro beat estimates with $0.87 EPS (vs. $0.69 consensus) and $373.91 million in revenue; the stock opened at $54.29, with a $2.20 billion market cap and a 24.13 P/E.
• Insider activity includes CEO Jack Bendheim selling 110,842 shares (a 47.4% cut to his position) and 294,165 insider shares sold in the past 90 days, while the company pays a quarterly dividend of $0.12 (≈0.9% yield) and insiders still own 50.13% of shares.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) is expected to be posting its Q3 2026 results after the market closes on Wednesday, May 6th. Analysts expect Phibro Animal Health to post earnings of $0.72 per share and revenue of $365.2050 million for the quarter. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. Individuals may review the information on the company's upcoming Q3 2026 earning report for the latest details on the call scheduled for Thursday, May 7, 2026 at 9:00 AM ET.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last released its earnings results on Wednesday, February 4th. The company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.18. The company had revenue of $373.91 million for the quarter, compared to the consensus estimate of $355.64 million. Phibro Animal Health had a net margin of 6.29% and a return on equity of 38.28%. On average, analysts expect Phibro Animal Health to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Phibro Animal Health Stock Down 3.3%

NASDAQ:PAHC opened at $54.29 on Wednesday. The company has a market cap of $2.20 billion, a PE ratio of 24.13, a P/E/G ratio of 0.86 and a beta of 0.69. Phibro Animal Health has a twelve month low of $18.20 and a twelve month high of $60.08. The company has a current ratio of 3.05, a quick ratio of 1.22 and a debt-to-equity ratio of 2.14. The company's 50 day moving average is $53.80 and its two-hundred day moving average is $46.00.

Phibro Animal Health Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, March 25th. Shareholders of record on Wednesday, March 4th were given a dividend of $0.12 per share. This represents a $0.48 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend was Wednesday, March 4th. Phibro Animal Health's payout ratio is currently 21.33%.

Analyst Ratings Changes

Several analysts have weighed in on the stock. Citigroup initiated coverage on shares of Phibro Animal Health in a research report on Wednesday, April 15th. They set a "neutral" rating and a $62.00 target price on the stock. Morgan Stanley set a $49.00 price objective on shares of Phibro Animal Health in a research note on Friday, February 6th. Finally, Zacks Research upgraded shares of Phibro Animal Health from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, March 11th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Phibro Animal Health has a consensus rating of "Hold" and a consensus price target of $42.40.

Insider Activity

In related news, CEO Jack Bendheim sold 110,842 shares of the business's stock in a transaction on Thursday, February 5th. The shares were sold at an average price of $48.38, for a total value of $5,362,535.96. Following the completion of the transaction, the chief executive officer directly owned 122,958 shares in the company, valued at $5,948,708.04. The trade was a 47.41% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In the last ninety days, insiders have sold 294,165 shares of company stock valued at $14,655,279. Insiders own 50.13% of the company's stock.

Hedge Funds Weigh In On Phibro Animal Health

Large investors have recently made changes to their positions in the company. State Street Corp raised its position in Phibro Animal Health by 5.4% during the fourth quarter. State Street Corp now owns 942,279 shares of the company's stock worth $35,204,000 after acquiring an additional 48,243 shares during the period. Millennium Management LLC raised its position in Phibro Animal Health by 4,227.1% during the fourth quarter. Millennium Management LLC now owns 641,313 shares of the company's stock worth $23,959,000 after acquiring an additional 626,492 shares during the period. Geode Capital Management LLC raised its position in Phibro Animal Health by 4.0% during the fourth quarter. Geode Capital Management LLC now owns 569,111 shares of the company's stock worth $21,265,000 after acquiring an additional 21,951 shares during the period. Dimensional Fund Advisors LP raised its position in Phibro Animal Health by 1.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 492,335 shares of the company's stock worth $18,394,000 after acquiring an additional 6,826 shares during the period. Finally, Invesco Ltd. raised its position in Phibro Animal Health by 22.5% during the third quarter. Invesco Ltd. now owns 322,299 shares of the company's stock worth $13,040,000 after acquiring an additional 59,226 shares during the period. 99.34% of the stock is currently owned by institutional investors and hedge funds.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation NASDAQ: PAHC is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro's portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.